Comparative efficacy of Go 10213 and some nitroimidazoles againstTrichomonas vaginalisandT. foetusin mice infected subcutaneously
- 1 April 1982
- journal article
- research article
- Published by Taylor & Francis in Pathogens and Global Health
- Vol. 76 (2), 175-178
- https://doi.org/10.1080/00034983.1982.11687524
Abstract
Go 10213, a new nitroimidazole, was compared with other nitroimidazoles such as metronidazole, tinidazole, secnidazole and nimorazole against the s.c. infection of mice with T. vaginalis and T. foetus. Go 10213 appears superior to the other nitroimidazoles in this model, and may therefore be of value against trichomoniasis in man. In early clinical trials, Go 10213 was active at a single dose of 600 mg kg-1. The suitability of the original test system is thus verified.This publication has 3 references indexed in Scilit:
- Comparative studies on the trichomonacidal activity of 5-nitroimidazole-derivatives in mice infected s.c. or intravaginally with T. vaginalisCellular and Molecular Life Sciences, 1977
- PROTECTIVE ACTION OF ANISOMYCIN IN MICE INFECTED WITH TRICHOMONAS-FOETUS1954
- Experimental Basis for the Chemotherapy of Trichomonas vaginalis Infestations. I.Experimental Biology and Medicine, 1943